Alliance Pharma Eyes OTC Acquisitions Following Strong 2021

UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.

SC1807_Market Growth_572387551_1200.jpg
• Source: Shutterstock

Alliance Pharma plc reported sales up by 23% to £170m ($232m) in 2021, thanks to the acquisition of the Amberen menopause supplement and the strong performance of scar-reduction treatment Kelo-Cote. With the group in a strong financial position, it is ready to pursue further M&A in 2022 to strengthen its consumer health offering.

More from Europe

More from Geography